JP2013543897A5 - - Google Patents

Download PDF

Info

Publication number
JP2013543897A5
JP2013543897A5 JP2013541034A JP2013541034A JP2013543897A5 JP 2013543897 A5 JP2013543897 A5 JP 2013543897A5 JP 2013541034 A JP2013541034 A JP 2013541034A JP 2013541034 A JP2013541034 A JP 2013541034A JP 2013543897 A5 JP2013543897 A5 JP 2013543897A5
Authority
JP
Japan
Prior art keywords
formulation
adrenergic receptor
patient
selective beta
lipophilic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013541034A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013543897A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/061973 external-priority patent/WO2012074856A2/en
Publication of JP2013543897A publication Critical patent/JP2013543897A/ja
Publication of JP2013543897A5 publication Critical patent/JP2013543897A5/ja
Pending legal-status Critical Current

Links

JP2013541034A 2010-11-24 2011-11-22 脂肪症及び輪郭の膨れの美容処置のための、選択的な、親油性の、及び長時間作用性のベータアゴニストの単剤療法製剤、及び方法 Pending JP2013543897A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41709810P 2010-11-24 2010-11-24
US61/417,098 2010-11-24
PCT/US2011/061973 WO2012074856A2 (en) 2010-11-24 2011-11-22 Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging

Publications (2)

Publication Number Publication Date
JP2013543897A JP2013543897A (ja) 2013-12-09
JP2013543897A5 true JP2013543897A5 (enExample) 2014-12-25

Family

ID=45475499

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013541034A Pending JP2013543897A (ja) 2010-11-24 2011-11-22 脂肪症及び輪郭の膨れの美容処置のための、選択的な、親油性の、及び長時間作用性のベータアゴニストの単剤療法製剤、及び方法

Country Status (17)

Country Link
US (2) US9597531B2 (enExample)
EP (1) EP2646012A4 (enExample)
JP (1) JP2013543897A (enExample)
KR (1) KR20140025312A (enExample)
CN (2) CN105832681A (enExample)
AU (1) AU2011336869B2 (enExample)
BR (1) BR112013012994A2 (enExample)
CA (1) CA2815374A1 (enExample)
EA (1) EA201270784A1 (enExample)
GB (1) GB2485885B (enExample)
GE (1) GEP201606551B (enExample)
IL (1) IL225879A0 (enExample)
MX (1) MX2013005873A (enExample)
SG (1) SG190878A1 (enExample)
TW (1) TW201231042A (enExample)
UA (1) UA111822C2 (enExample)
WO (1) WO2012074856A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2384641T3 (es) 2005-07-14 2012-07-10 Lithera, Inc. Formulación lipolítica que potencia la liberación mantenida para el tratamiento localizado del tejido adiposo
PL2077830T3 (pl) * 2006-10-17 2013-04-30 Lithera Inc Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
BR112012017556A2 (pt) * 2010-01-15 2016-08-16 Lithera Inc formulações de torta liofilizada
EP4161496A4 (en) * 2020-06-04 2024-08-21 Curasen Therapeutics, Inc. FORMS AND COMPOSITIONS OF A BETA-ADRENERGIC AGONIST

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3898330A (en) 1973-08-01 1975-08-05 Squibb & Sons Inc Corticosteroid phosphate salts/neomycin sulfate ophthalmic
US4525359A (en) * 1982-12-10 1985-06-25 Greenway Frank L Iii Treatment for selective weight control
NZ212204A (en) 1984-06-04 1988-07-28 Merck & Co Inc Growth-promoting compositions containing hydroxylic compounds
GB8426672D0 (en) 1984-10-22 1984-11-28 Erba Farmitalia Pharmaceutical compositions
JPH0696521B2 (ja) 1986-01-31 1994-11-30 千寿製薬株式会社 眼局所投与用眼圧降下剤
FR2602423B1 (fr) 1986-08-08 1989-05-05 Ethypharm Sa Procede de preparation d'un medicament a base de fenofibrate, medicament obtenu par ce procede
US5270305A (en) 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
CA2030174C (en) 1990-01-10 1996-12-24 Anthony H. Cincotta Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
US5126147A (en) 1990-02-08 1992-06-30 Biosearch, Inc. Sustained release dosage form
US5919827A (en) 1990-07-11 1999-07-06 Sepracor Inc. Method for treating asthma using optically pure R(-) salmeterol
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
SK282826B6 (sk) 1991-12-18 2002-12-03 Aktiebolaget Astra Farmaceutická kompozícia na podávanie inhaláciou s obsahom formoterolu a budesonidu a jej použitie
US5314916A (en) 1993-04-19 1994-05-24 Alcon Laboratories, Inc. B2 adrenegic agonists and use thereof in the treatment of glaucoma
US6316443B1 (en) 1994-08-04 2001-11-13 Merck & Co., Inc. Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a β-adrenergic antagonist
GB9512854D0 (en) 1995-06-23 1995-08-23 Wellcome Found Novel formulation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
AU4582797A (en) 1996-09-13 1998-04-02 Regents Of The University Of California, The Methods for treatment of retinal diseases
ATE413415T1 (de) 1996-09-19 2008-11-15 Univ Michigan Polymere enthaltend polysaccharide wie alginate oder modifizierte alginate
SE9700135D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
TW469832U (en) 1997-03-14 2001-12-21 Astra Ab Inhalation device
CN1269722A (zh) 1997-03-18 2000-10-11 Basf公司 调节对皮质类固醇反应的方法及组合物
US6656508B2 (en) 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
WO1998048810A1 (en) 1997-04-30 1998-11-05 Bridge Pharma, Inc. Composition and methods using an eutomer
US20010044584A1 (en) 1997-08-28 2001-11-22 Kensey Kenneth R. In vivo delivery methods and compositions
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
JPH11106334A (ja) * 1997-09-30 1999-04-20 Saitama Daiichi Seiyaku Kk 尿失禁治療剤
US20030095925A1 (en) 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20040152664A1 (en) 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
US6384259B1 (en) 1998-11-16 2002-05-07 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and dosage form
WO2001019373A2 (en) 1999-09-17 2001-03-22 Basf Aktiengesellschaft Methods and compositions for modulating responsiveness to corticosteroids
GB9924992D0 (en) 1999-10-21 1999-12-22 Glaxo Group Ltd Pharmaceutical aerosol formulations
US6569903B2 (en) 1999-12-07 2003-05-27 Rohto Pharmaceutical Co., Ltd. Ophthalmic compositions
US20040208910A1 (en) 2000-04-26 2004-10-21 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of adrenergic agents
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
AUPQ797700A0 (en) 2000-06-06 2000-06-29 Austin Research Institute, The Vaccine
US6936426B2 (en) 2000-10-06 2005-08-30 Harbor-Ucla Research And Education Institute Detection of antibody mediated inflammatory auto-immune disorders
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
JP2004513340A (ja) 2000-11-03 2004-04-30 ヒストオテック エーピーエス 組織ブロックを切片化するための装置および方法
ES2260321T3 (es) 2000-12-07 2006-11-01 Universiteit Utrecht Holding B.V. Composicion para el tratamiento de transtornos inflamatorios.
US20030022856A1 (en) 2001-01-30 2003-01-30 The Regents Of The University Of Michigan Method for sustained release local delivery of drugs for ablation of unwanted tissue
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
MY137522A (en) 2001-04-30 2009-02-27 Glaxo Group Ltd Novel anti-inflammatory androstane derivatives.
GB0124523D0 (en) 2001-10-12 2001-12-05 Glaxo Group Ltd Pharmaceutical combination
JP2005508220A (ja) 2001-10-24 2005-03-31 パーリ・ゲーエムベーハー 薬用組成物調製用具
US6625078B2 (en) 2002-02-11 2003-09-23 United Memories, Inc. Look-ahead refresh for an integrated circuit memory
US8541399B2 (en) 2002-02-19 2013-09-24 Resolution Chemicals Limited Solvent-based sterilisation of pharmaceuticals
US20050009798A1 (en) 2002-02-20 2005-01-13 Sepracor Inc. Carbonate and carbamate modified forms of glucocorticoids in combination with B2 adrenergic agonists
US6643212B1 (en) 2002-04-18 2003-11-04 United Memories, Inc. Simultaneous function dynamic random access memory device technique
AU2003263717A1 (en) 2002-09-25 2004-04-19 Astrazeneca Ab A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
CA2500065A1 (en) 2002-09-30 2004-04-15 Acusphere, Inc. Sustained release porous microparticles for inhalation
US20040208833A1 (en) 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
EP1613266A4 (en) 2003-04-15 2009-05-06 Theraquest Biosciences Llc METHOD FOR TREATING PAIN AND COMPOSITIONS FOR USE THEREOF
US9808471B2 (en) 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
WO2004103057A2 (en) * 2003-05-15 2004-12-02 The University Of Georgia Research Foundation, Inc. Compositions and methods for inducing adipose tissue cell death
EP1635844A1 (en) 2003-05-22 2006-03-22 ALTANA Pharma AG Salmeterol and ciclesonide combination
SE0302029D0 (sv) 2003-07-07 2003-07-07 Astrazeneca Ab Novel process
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
GB2403655A (en) 2003-07-11 2005-01-12 Cipla Ltd Combined pharmaceutical product comprising a beta-2 adrenoreceptor agonist & an antihistamine for treatment of respiratory diseases such as asthma
JP2007508240A (ja) 2003-07-22 2007-04-05 バクスター・インターナショナル・インコーポレイテッド 低分子量有機分子の小球状粒子ならびにその調製方法および使用方法
BRPI0414907A (pt) 2003-09-30 2006-11-07 Acusphere Inc formulações farmacêuticas com liberação sustentada injetáveis, orais ou tópicas
US20050075900A1 (en) 2003-10-02 2005-04-07 Arguimbau Vincent C. Method and apparatus for bulk food marking and tracking with supplier rating system
DE10347994A1 (de) 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
CN105820160B (zh) 2003-11-05 2019-02-12 萨可德生物科学公司 细胞粘着调节剂
AU2004292416B2 (en) * 2003-11-20 2010-01-28 Alteragon Pty Ltd Method of decreasing fat deposits and body weight in mammals and birds
KR100573828B1 (ko) 2003-12-29 2006-04-26 주식회사 하이닉스반도체 셀데이터의 손실을 방지하기 위한 반도체 메모리 소자
US20080270175A1 (en) 2003-12-31 2008-10-30 Klinger Advanced Aesthetics, Inc. Systems and methods using a dynamic expert system to provide patients with aesthetic improvement procedures
US20050212152A1 (en) 2004-03-23 2005-09-29 Reens Daniel J System and method for humidifying homes and commercial sites
US7754230B2 (en) 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
US7317023B2 (en) 2004-07-21 2008-01-08 Theravance, Inc. Diaryl ether β2 adrenergic receptor agonists
EP1819318A1 (en) 2004-11-24 2007-08-22 Seo Hong Yoo Dried forms of aqueous solubilized bile acid dosage formulation
EP1867334A4 (en) 2005-02-18 2009-07-15 Santen Pharmaceutical Co Ltd METHOD FOR RELIEVING OR AVOIDING A SECONDARY EFFECT OF A STEROID COMPOUND
WO2006108176A2 (en) 2005-04-08 2006-10-12 The Regents Of The University Of California Wound healing composition
US7931909B2 (en) 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
CN1706501A (zh) 2005-05-27 2005-12-14 沈阳药科大学 亲脂性药物环糊精包合物的制备方法
CN101252842A (zh) * 2005-07-14 2008-08-27 利波西拉公司 用于局部脂肪组织治疗的持续释放的增强性脂肪分解性制剂
ES2384641T3 (es) 2005-07-14 2012-07-10 Lithera, Inc. Formulación lipolítica que potencia la liberación mantenida para el tratamiento localizado del tejido adiposo
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
FR2893845B1 (fr) 2005-11-30 2010-10-29 Galderma Sa Composition sous forme de spray comprenant un corticoide et une phase huileuse
EP1973523A2 (en) 2005-12-15 2008-10-01 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
US20070178051A1 (en) 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
JP2009532489A (ja) 2006-04-03 2009-09-10 テバ ファーマシューティカル インダストリーズ リミティド 薬剤微粒子
DE102007026979A1 (de) 2006-10-06 2008-04-10 Friedrich Siller Inhalationsvorrichtung
CN101626759B (zh) * 2006-10-17 2014-08-06 利特拉公司 用于治疗甲状腺眼病的组合物和制剂
PL2077830T3 (pl) * 2006-10-17 2013-04-30 Lithera Inc Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej
US20100063006A1 (en) 2006-11-22 2010-03-11 American Network Of Lipolysis, Llc Compositions and methods to reduce fat and retract skin
WO2008122118A1 (en) 2007-04-04 2008-10-16 Theratechnologies Inc. Pharmaceutical formulations of ghrh molecules
ES2592289T3 (es) * 2007-04-24 2016-11-29 Acacia Pharma Limited Combinación de fármacos y su uso en el tratamiento de la pérdida de músculo
US20090208492A1 (en) 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
SI2170348T1 (sl) 2007-06-22 2016-12-30 Dompe Farmaceutici S.P.A. Šumeče tablete za inhalacijsko uporabo
US20090131386A1 (en) 2007-11-13 2009-05-21 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
WO2009073051A1 (en) 2007-12-03 2009-06-11 Bridge Pharma, Inc. Use of rr/sr-ractopamine
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
BR112012017556A2 (pt) 2010-01-15 2016-08-16 Lithera Inc formulações de torta liofilizada

Similar Documents

Publication Publication Date Title
AU2016222802B2 (en) Reduction of adipose tissue
JP2017533972A5 (enExample)
JP2013522303A5 (enExample)
JP2014098041A5 (enExample)
RU2019100425A (ru) Новая доза и препаративная форма
NZ611628A (en) Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients
JP2013543897A5 (enExample)
EA201590166A8 (ru) Комбинированная терапия для лечения рассеянного склероза
RU2016141314A (ru) Составы разагилина с пролонгированным высвобождением и их применение
JP2013516493A5 (enExample)
JP2017081920A (ja) サキシトキシン誘導体での触覚の喪失の処置
JP6768646B2 (ja) Pgi2受容体に関連した状態の治療法
KR20140014404A (ko) 국소 지방 조직 치료를 위한 투여 방법 및 제제
ES2265495T3 (es) Uso de tramadol para el retardo de la eyaculacion.
RU2014113334A (ru) Применение ингибитора ароматазы для лечения гипогонадизма и родственных заболеваний
JP2015522033A5 (enExample)
JP2024546605A (ja) がんを治療するための併用療法の使用
JP2020500864A5 (enExample)
TWI441639B (zh) 用於治療卵巢癌之包含紫杉醇之組合
KR20120023754A (ko) Ave8062 및 소라페닙을 포함하는 항종양 조합물
JP2016505050A5 (enExample)
MX2009002311A (es) Composiciones farmaceuticas para tratamiento de infecciones fungales.
JP2012525358A5 (enExample)
HRP20240812T1 (hr) Oblici doziranja i terapijska primjena l-4-klorokinurenina
JP2008517991A5 (enExample)